Differential expression of urokinase-type plasminogen activator, its receptor, and inhibitors in mouse skin after exposure to a tumor-promoting phorbol ester

Journal of Investigative Dermatology

Volumn 106, Issue 4, 1996, Pages 622-630

  Lund, Leif R ^a   Eriksen, Jens ^b   Ralfkiær, Elisabeth ^b   Rømer, John ^a  

^a FINSEN LABORATORY   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Chemical carcinogenesis; Phorbol myristate acetate; Plasminogen activation; Stromal epithelial interactions

Indexed keywords

MESSENGER RNA; PHORBOL ESTER; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN TUMOR;

EID: 0029944555     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1111/1523-1747.ep12345425     Document Type: Article

References (60)

1. Akhurst RJ, Fee F, Baimain A: Localized production of TGF-β mRNA in tumour promoter-stimulated mouse epidermis. Nature 331:363-365, 1988
2. Alonso S, Minty A, Bourlet Y, Buckingham M: Comparison of three actin-coding sequences in the mouse: evolutionary relationships between the actin genes of the warm-blooded vertebrates. J Mol Evol 23:11-22, 1986
3. Andreasen PA, Georg B, Lund LR, Riccio A, Stacey SN: Plasminogen activator inhibitors: hormonally regulated serpins. Mol Cell Endocrinol 68:1-19, 1990
4. 2-terminal amino acid sequence and glycosylation variants. J Biol Chem 265:16453-6460, 1990
5. Belin D, Vassalli J-D, Combepine C, Godeau F, Nagamine Y, Reich E, Kocher HP, Duvoisin RM: Cloning, nucleotide sequencing and expression of cDNAs encoding mouse urokinase-type plasminogen activator. Eur J Biochem 148:225-232, 1985
6. Belin D, Wohlwend A, Schleuning W-D, Kruithof EKO, Vassalli JD: Facultative polypeptide translocation allows a single mRNA to encode the secreted and cytosolic forms of plasminogen activators inhibitor 2. EMBO J 8:3287-3294, 1989
7. Blasi F, Vassalli J-D, Danø K: Urokinase-type plasminogen activator: Proenzyme, receptor, and inhibitors. J Cell Biol 104:801-804, 1987
8. Bowden GT, Krieg P: Differential gene expression during multistage carcinogenesis. Environ Health Perspect 93:51-56, 1991
9. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159, 1987
10. Craig AM, Smith JH, Denhardt DT: Osteopontin, a transformation-associated cell adhesion phosphoprotein, is induced by 12-O-tetradecanoylphorbol 13-acetate in mouse epidermis. J Biol Chem 264:9682-9689, 1989
11. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L: Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44:139-266, 1985
12. Danø K, Behrendt N, Brünner N, Ellis V, Ploug M, Pyke C: The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis 8:189-203, 1994
13. Danø K, Grøndahl-Hansen J, Eriksen J, Nielsen BS, Rømer J, Pyke C: The receptor for urokinase plasminogen activator: stromal cell involvement in extracellular proteolysis during cancer invasion. In: Barrett AJ, Bond I (eds.). Proteolysis and Protein Turnover, Portland Press, London, 1994, pp 239-245
14. Ellis V, Behrendt N, Danø K: Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. J Biol Chem 266:12752-12758, 1991
15. Ellis V, Danø K: Plasminogen activation by receptor-bound urokinase. Sem Thromb Hemostas 17:194-200, 1991
16. Fowlis DJ, Flanders KC, Duffie E, Balmain A, Akhurst RJ: Discordant transforming growth factor β 1 RNA and protein localization during chemical carcinogenesis of the skin. Cell Growth Differ 3:81-91, 1992
17. Fuchs E: Epidermal differentiation: the bare essentials. J Cell Biol 111:2807-2814, 1990
18. Grøndahl-Hansen J, Lund LR, Ralfkiær E, Ottevanger V, Danø K: Urokinase- and tissue-type plasminogen activators in keratinocytes during wound reepithelialization in vivo. J Invest Dermatol 90:790-795, 1988
19. Gupta AK, Fisher GJ, Elder JT, Talwar HS, Esmann J, Duell EA, Nickoloff BJ, Voorhees JJ: Topical cyclosporine A inhibits the phorbol ester induced hyperplastic inflammatory response but not protein kinase C activation in mouse epidermis, J Invest Dermatol 93:379-386, 1989
20. Holladay K, Fujiki H, Bowden GT: Okadaic acid induces the expression of both early and secondary response genes in mouse keratinocytes. Mol Carcinogenesis 5:16-24, 1992
21. Jemen PH, Lorand L, Ebbesen P, Gliemann J: Type-2 plasminogen-activator inhibitor is a substrate for trophoblast transglutaminase and factor XIIIa. Transglutaminase-catalyzed cross-linking to cellular and extracellular structures. Eur J Biochem 214:141-146, 1993
22. Keski-Oja J, Blasi F, Leof EB, Moses HL: Regulation of the synthesis and activity of urokinase plasminogen activator in A549 human lung carcinoma cells by transforming growth factor-β. J Cell Biol 106:451-459, 1988
23. Krieg P, Schnapke R, Fürstenberger G, Vogt I, Marks F: TGFβ1 and skin carcinogenesis: antiproliferative effect in vitro and TGFβ1 mRNA expression during epidermal hyperproliferation and multistage tumorigenesis. Mol Carcinogenesis 4:129-137, 1991
24. Kristensen P, Eriksen J, Blasi F, Danø K: Two alternatively spliced mouse urokinase receptor mRNAs with different histological localization in the gastrointestinal tract. J Cell Biol 115:1763-1771, 1991a
25. Kristensen P, Eriksen J, Danø K: Localization of urokinase-type plasminogen activator messenger RNA in the normal mouse by in situ hybridization. J Histochem Cytochem 39:341-349, 1991b
26. Laiho M, Keski-Oja J: Growth factors in the regulation of pericellular proteolysis: A review. Cancer Res 49:2533-2553, 1989
27. Lund LR, Ellis V, Rønne E, Pyke C, Danø K: Transcriptional and posttranscrip-tional regulation of the receptor for urokinase plasminogen activator by cytokines and tumor promoters in the human lung carcinoma cell line A549. Biochem J 310:345-352, 1995
28. Lund LR, Georg B, Nielsen LS, Mayer M, Danø K, Andreasen PA: Plasminogen activator inhibitor type 1: cell-specific and differentiation-induced expression and regulation in human cell lines, as determined by enzyme-linked immunosorbent assay. Mol Cell Endocrinol 60:43-53, 1988
29. Lund LR, Riccio A, Andreasen PA, Nielsen LS, Kristensen P, Laiho M, Saksela O, Blasi F, Danø K: Transforming growth factor-beta is a strong and fast acting positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts. EMBO J 6:1281-1286, 1987
30. Lund LR, Rømer J, Rønne E, Ellis V, Blasi F, Danø K: Urokinase-receptor biosynthesis, mRNA level and gene transcription are increased by transforming growth factor-β 1 in human A549 lung carcinoma cells. EMBO J 10:3399-3407, 1991a
31. Lund LR, Rønne E, Roldan AL, Behrendt N, Rømer J, Blasi F, Danø K: Urokinase receptor mRNA level and gene transcription are strongly and rapidly increased by phorbol myristate acetate in human monocyte-like U937 cells. J Biol Chem 266:5177-5181, 1991b
32. Lyons-Giordano B, Loskutoff D, Chen CS, Lazarus G, Keeton M, Jensen PJ: Expression of plasminogen activator inhibitor type 2 in normal and psoriatic epidermis. Histochemistry 101:105-112, 1994
33. Mayer M, Lund LR, Riccio A, Skouv J, Nielsen LS, Stacey SN, Danø K, Andreasen PA: Plasminogen activator inhibitor type-1 protein, mRNA and gene transcription are increased by phorbol esters in human rhabdomyosarcoma cells. J Biol Chem 263:15688-15693, 1988
34. Mignatti P, Rifkin DB: Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 73:161-195, 1993
35. Miller SJ, Jensen PJ, Dzubow LM, Lazarus GS: Urokinase plasminogen activator is immunocytochemically detectable in squamous cell but not basal cell carcinomas. J Invest Dermatol 98:351-358, 1992
36. Oberyszyn TM, Sabourin CLK, Bijur GN, Oberyszyn AS, Boros LG, Robertson FM: Interleukin-1α gene expression and localization of interleukin-1α protein during tumor promotion. Mol Carcinogenesis 7:238-248, 1993
37. Ostrowski LE, Finch J, Krieg P, Matrisian L, Patskan G, O'Connell JF, Phillips J, Slaga TJ, Breathnach R, Bowden GT: Expression pattern of a gene for a secreted metalloproteinase during late stages of tumor progression. Mol Carcinogenesis 1:13-19, 1988
38. Picone R, Kajtaniak EL, Nielsen LS, Behrendt N, Mastronicola MR, Cubellis MV, Stoppelli MP, Pedersen S, Danø K, Blasi F: Regulation of urokinase receptors in monocytelike U937 cells by phorbol ester phorbol myristate acetate. J Cell Biol 108:693-702, 1989
39. Ploug M, Rønne E, Behrendt N, Jemen AL, Blasi F, Danø K: Cellular receptor for urokinase plasminogen activator, Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylmositol. J Biol Chem 266:1926-1933, 1991
40. Potten CS: Cell replacement in epidermis (keratopoiesis) via discrete units of proliferation. Int Rev Cytol 69:271-318, 1981
41. Prendergast GC, Cole MD: Posttranscriptional regulation of cellular gene expression by the c-myc oncogene. Mol Cell Biol 9:124-134, 1989
42. Pyke C, Rømer J, Kallunki P, Lund LR, Ralfkiær E, Danø K, Tryggvason K: The γ2 chain of kalinin/laminin 5 is preferentially expressed in invading malignant cells in human canters. Am J Pathol 145:782-791, 1994
43. Quax PHA, van den Hoogen CM, Verheijen JH, Padro T, Zeheb R, Gelehrter TD, van Berkel TJC, Kuiper J, Emeis JJ: Endotoxin induction of plasminogen activator and plasminogen activator inhibitor type 1 mRNA in rat tissues in vivo. J Biol Chem 205:15560-15563, 1990
44. Reiners JJ Jr, Slaga TJ: Effects of tumor promoters on the rate and commitment to terminal differentiation of subpopulations of murine keratinocytes. Cell 32:247-255, 1983
45. Roldan AL, Cubells MV, Masucci MT, Behrendt N, Lund LR, Danø K, Appella E. Blasi F: Cloning and expression of the receptor tor human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J 9:467-474, 1990
46. Rømer J, Lund LR, Eriksen J, Pyke C, Kristensen P, Danø K: The receptor for urokinase-type plasminogen activator is expressed by keratinocytes at the leading edge during re-epithelialization od mouse skin wounds. J Invest Dermatol 102: 519-522, 1994
47. Rømer J, Lund LR, Eriksen J, Ralfkiær E, Zeheb R, Gelehrter TD, Danø K, Kristensen P: Differential expression of urokinase-type plasminogen activator and its type-1 inhibitor during healing of mouse skin wounds. J Invest Dermatol 97:803-811, 1991
48. Rose-John S, Fürstenberger G, Krieg P, Besemfelder E, Rincke G, Marks F: Differential effects of phorbol esters on c-fos and c-myc and ornithine decarboxylase gene expression in mouse skin in vivo. Carcinogenesis 9:831-835, 1988
49. Saksela O, Rifkin DB: Cell-associated plasminogen activation: regulation and physiological functions. Ann Rev Cell Biol 4:93-126, 1988
50. Sappino A-P, Belin D, Huarte J, Hirschel-Scholz S, Saurat J-H, Vassalli J-D: Differential protease expression by cutaneous squamous and basal cell carcinomas. J Clin Invest 88:1073-1079, 1991
51. Sawdey MS, Loskutoff DJ: Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest 88:1346-1333, 1991
52. Schleuning WD, Medcalf RL, Hession C, Rothenbühler R, Shaw A, Kruithof EKO: Plasminogen activator inhibitor 2: regulation of gene transcription during phorbol ester-mediated differentiation of U-937 human histiocytic lymphoma cells. Mol Cell Biol 7:4564-4567, 1987
53. Slaga TJ: Overview ot tumor promotion in animals. Environ Health Perspect 50:3-14, 1983
54. Solberg H, Løber D, Eriksen J, Ploug M, Rønne E, Behrendt N, Danø K, Hoyer-Hansen G: Identification and characterization of the murine cell surface receptor for the urokinase-type plasminogen activator. Eur J Biochem 205:451-458, 1992
55. Stoppelli MP, Verde P, Grimaldi CJ, Locatelli EK, Blasi F: Increase in urokinase plasminogen activator mRNA synthesis in human carcinoma cells is a primary effect of the potent tumor promoter, phorbol myristate acetate. J Cell Biol 102:1235-1241, 1986
56. Thacher SM, Rice RH: Keratinocyte-specific transglutaminase of cultured human epidermal cells: Relation to cross-linked envelope formation and terminal differentiation. Cell 40:685-695, 1985
57. Vassalli JD, Haccino D, Belin D: A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol 100:86-92, 1985
58. Wigler M, Weinstein IB: Tumour promoter induces plasminogen activator. Nature 259:232-233, 1976
59. Wright JH, McDonnell S, Portella G, Bowden GT, Baimain A, Matrisian LM: A switch from stromal to tumor cell expression of stromelysin-1 mRNA associated with the conversion of squamous to spindle carcinomas during mouse skin tumor progression. Mol Carcinogenesis 10:207-215, 1994
60. Yuspa SH, Poirier MC.: Chemical carcinogenesis: from animal models to molecular models in one decade. Adv Cancer Res 50:25-70, 1988